<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642642</url>
  </required_header>
  <id_info>
    <org_study_id>IT-A-008</org_study_id>
    <nct_id>NCT00642642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring</brief_title>
  <official_title>A Phase II/III Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Isolagen Therapy in the Treatment of Moderate to Sever Facial Acne Scarring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fibrocell Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fibrocell Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile and the treatment effect of
      Isolagen TherapyTM and placebo when administered to facial acne scars.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluator Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) and four months after last treatment</time_frame>
    <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) and four months after last treatment</time_frame>
    <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluator Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) compared to one, two, and three months after last treatment</time_frame>
    <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) compared to one, two, and three months after last treatment</time_frame>
    <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Acne Scarring of the Face</condition>
  <arm_group>
    <arm_group_label>Double blinded active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive autologous fibroblast treatment on either their left or right side of their face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double blinded placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive placebo treatment on the opposite side of the face from active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Human Fibroblasts (azficel-T)</intervention_name>
    <description>Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart.</description>
    <arm_group_label>Double blinded active</arm_group_label>
    <other_name>LAVIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart.</description>
    <arm_group_label>Double blinded placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, between 18 years and 65 years of age.

          2. Investigator assessment of the acne scarring on each cheek of moderate to severe.

          3. A history of acne scarring for more than 3 years.

          4. Subject assesses the appearance of both sides of their facial acne scars as
             dissatisfied or very dissatisfied with appearance.

        Exclusion Criteria:

          1. Significant active acne.

          2. Use of oral antibiotic or retinoid active acne therapy within one year of enrollment.

          3. Presence of hypertrophic scars on the cheeks.

          4. More than 20% of treatment area comprised of ice pick scars or sinus tracts

          5. Treatment area per cheek is less than 9 cm x cm

          6. Unilateral or unbalanced acne scar distribution.

          7. Physical attributes which prevent the assessment or treatment of the acne scars.

          8. Treatment with an investigational product or procedure within 30 days prior to study
             enrollment or plans to participate in another clinical trial during the course of this
             study.

          9. Previous treatment with Isolagen TherapyTM.

         10. Use of Isotretinoin within one year of enrollment into study.

         11. Use of permanent or semi-permanent dermal fillers in the treatment areas within
             defined time frames.

         12. Disorders or drugs that increase bleeding or clotting.

         13. Pregnant or lactating women or women trying to become pregnant during the study.

         14. Excessive exposure to sun.

         15. Smoking more than ½ pack of cigarettes per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brighton Medical Corporation</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Laser Institute for Dermatology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute, LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser, Skin and Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser and Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <results_first_submitted>February 9, 2012</results_first_submitted>
  <results_first_submitted_qc>July 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2013</results_first_posted>
  <last_update_submitted>July 19, 2013</last_update_submitted>
  <last_update_submitted_qc>July 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between 7 Nov 2007 and 6 March 2008</recruitment_details>
      <pre_assignment_details>Patients were enrolled and biopsied for manufacture of study product. Patients for whom study product could not be manufactured were excluded from the Intent to Treat (ITT) population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Autologous Fibroblasts and Placebo</title>
          <description>Patients were treated with autologous fibroblasts on one cheek, and placebo on the opposite cheek</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Biopsy &amp; Product Manufacture</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109">Patients biopsied and for whom study product could be produced are considered completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment &amp; Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous Fibroblasts and Placebo</title>
          <description>Patients were treated with autologous fibroblasts on one cheek, and placebo on the opposite cheek</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluator Live Acne Scarring Assessment Responders</title>
        <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
        <time_frame>Baseline (prior to first treatment) and four months after last treatment</time_frame>
        <population>Analysis population was the ITT population, defined as subjects for whom product could be produced and who were randomized to study treatment, whether or not all study treatments are actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Fibroblasts Cheeks</title>
            <description>Cheeks treated with autologous fibroblasts (azficel-T)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cheeks</title>
            <description>Cheeks treated with placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluator Live Acne Scarring Assessment Responders</title>
          <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
          <population>Analysis population was the ITT population, defined as subjects for whom product could be produced and who were randomized to study treatment, whether or not all study treatments are actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference in the response rates between the two treatment arms.
Statistical test: McNemar’s paired test of proportions Significance level: two sided alpha of 0.05 for each of the two co-primary endpoints.
Assumptions for power calculations:
Response rate for azficel-T treated cheek = 40% Response rate for placebo treated cheek = 20% 10% dropout rate; dropouts counted as failures. Low correlation between cheeks &amp; 50% correlation between endpoints</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>a priori threshold for statistical significance was 0.05</p_value_desc>
            <method>McNemar</method>
            <method_desc>Paired test of proportions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Live Acne Scarring Assessment Responders</title>
        <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
        <time_frame>Baseline (prior to first treatment) and four months after last treatment</time_frame>
        <population>Analysis was performed on the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Fibroblast Cheeks</title>
            <description>Cheeks treated with autologous fibroblasts</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cheeks</title>
            <description>Cheeks treated with placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Live Acne Scarring Assessment Responders</title>
          <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
          <population>Analysis was performed on the ITT population</population>
          <units>Cheeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference in the response rates between the two treatment arms.
Statistical test: McNemar’s paired test of proportions Significance level: two sided alpha of 0.05 for each of the two co-primary endpoints.
Assumptions for power calculations:
Response rate for azficel-T treated cheek = 40% Response rate for placebo treated cheek = 20% 10% dropout rate; dropouts counted as failures. Low correlation between cheeks &amp; 50% correlation between endpoints</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>a priori threshold for statistical significance = 0.05</p_value_desc>
            <method>McNemar</method>
            <method_desc>paired test of proportions</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluator Live Acne Scarring Assessment Responders</title>
        <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
        <time_frame>Baseline (prior to first treatment) compared to one, two, and three months after last treatment</time_frame>
        <population>Number of cheeks for analysis was the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Fibroblasts Cheeks</title>
            <description>Cheeks treated with autologous fibroblasts (azficel-T)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cheeks</title>
            <description>Cheeks treated with placebo solution</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluator Live Acne Scarring Assessment Responders</title>
          <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders. On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
          <population>Number of cheeks for analysis was the ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Months Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Live Acne Scarring Assessment Responders</title>
        <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
        <time_frame>Baseline (prior to first treatment) compared to one, two, and three months after last treatment</time_frame>
        <population>Analysis was performed on the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous Fibroblast Cheeks</title>
            <description>Cheeks randomized to receive autologous fibroblast treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cheeks</title>
            <description>Cheeks randomized to receive placebo treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Live Acne Scarring Assessment Responders</title>
          <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders. On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
          <population>Analysis was performed on the ITT population</population>
          <units>Cheeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Months Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of patient biopsy through the final study visit, four months after final study treatment (five months after first study treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous Fibroblast Cheeks</title>
          <description>Cheeks randomized to receive autologous fibroblast treatment</description>
        </group>
        <group group_id="E2">
          <title>Placebo Cheeks</title>
          <description>Cheeks randomized to receive placebo treatment</description>
        </group>
        <group group_id="E3">
          <title>Non-treatment Area Adverse Events</title>
          <description>Systemic adverse events and adverse events that occured outside of the study treatment area will be reported in this group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <description>Patient treated for overdose of recreational drugs after being biopsied and enrolled in the study, but prior to receiving any study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Administration site conditions</description>
                <counts group_id="E1" events="29" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E2" events="29" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Administration site condition</description>
                <counts group_id="E1" events="33" subjects_affected="11" subjects_at_risk="122"/>
                <counts group_id="E2" events="29" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications or presentations by the Investigator or his associates, were required to be submitted to the sponsor for review and approval prior to publication or presentation in any form.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr/ Joseph Fratantoni</name_or_title>
      <organization>Biologics Consulting Group</organization>
      <phone>(301) 340-8432</phone>
      <email>jfratantoni@bcg-usa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

